

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Cagnoni, et al.	}	EXAMINER:
SERIAL NO.:	10/598,869		ART UNIT: 1614
FILED:	May 31, 2007		CONFIRMATION NO.: 1638
TITLE:	COADMINISTRATION OF RADIATION, EFAPROXIRAL SODIUM, AND SUPPLEMENTAL OXYGEN FOR THE TREATMENT OF CANCER		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies of required documents enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:


- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action of the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

Date: August 30, 2007

A handwritten signature in cursive script, reading "Mary Breen Smith", written over a horizontal line.

Mary Breen Smith, #43,512
Swanson & Bratschun, L.L.C.
8210 Southpark Terrace
Littleton, CO 80120
Telephone: (303) 268-0066
Facsimile: (303) 268-0065

S:\CLIENTFOLDERS\ALLOS\07\PCT\US\IDS 2.DOC

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 1 of 1	ATTY. DOCKET NO. ALL.07/PCT-US	SERIAL NO. 10/598,869
	APPLICANT Cagnoni, et al.	
	FILING DATE May 31, 2007	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AA	2003-0232887	12/18/2003	Johnson, et al.			
	AB	4,014,329	03/29/97	Welch			
	AC	4,698,387	10/06/1987	Schmidt et al.			
	AD	4,886,487	12/12/89	Solem			
	AE	5,378,227	01/03/95	O'Riordan			
	AF	5,387,672	02/07/1995	Bucci et al.			
	AG	5,703,118	12/30/97	Durand			
	AH	5,853,388	12/29/98	Semel			
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	AK	DE 43 27 365	02/16/95	Germany			
	AL	WO 92/20335	11/26/1992	WIPO			
	AM						
	AN						
	AO						
	AP						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AQ	Abraham (2004) "Drug Discovery in Academia – A Case Study" Chem. Drug. Disc. 457-484
	AR	Gray R. (1988) "A Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk" Annals of Statistics 16:1141-1154
	AS	Khandelwal et al (1996) "Increased Radiation Response of FSaII Fibrosarcomas in C3H Mice Following Administration of an Allosteric Effector of Hemoglobin-Oxygen Affinity" Rad. Oncol. Invest. 4:51-59
	AT	Kleinberg et al. "Phase I Trial to Determine the Safety, Pharmacodynamics, and Pharmacokinetics of RSR13, a Novel Radioenhancer, in Newly Diagnosed Glioblastoma Multiforme" Journal of Clinical Oncology 1999 v.17 pp2593-2603
	AU	Leibel et al., Textbook of Radiation Oncology (1998) Chapters 13 and 14
	AAA	Padawer et al. (1981) "Combined Treatment with Radioestradiol-Lucanthone in Mouse C3HBA Mammary Adenocarcinoma and with Estradiol-Lucanthone in an Estrogen Bioassay" Int. J. Radiat. Oncol. Biol. Phys. 7:347-357
	AAB	Graham L.: "An Introduction to Medicinal Chemistry" 1995, OXFORD UNIVERSITY PRESS, New York page 58-60
	AAC	Wei (1993) "Effect of local change in O ₂ saturation of hemoglobin on cerebral vasodilation from hypoxia and hypotension" v265 pp1439-1443
	AAD	
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		